http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 23 Jul 2026 08:43:32 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Incyte+%28INCY%29+PT+Raised+to+%24104+at+Morgan+Stanley/26805327.html Morgan Stanley analyst Judah C. Frommer raised the price target on Incyte (NASDAQ: INCY) to $104.00 (from $103.00) while maintaining a Equalweight rating. http://www.streetinsider.com/Analyst+PT+Change/Incyte+%28INCY%29+PT+Raised+to+%24104+at+Morgan+Stanley/26805327.html Thu, 23 Jul 2026 08:43:32 -0400 INCY http://www.streetinsider.com/Analyst+PT+Change/Incyte+%28INCY%29+PT+Raised+to+%24110+at+JPMorgan/26804668.html JPMorgan analyst Jessica Fye raised the price target on Incyte (NASDAQ: INCY) to $110.00 (from $105.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/Incyte+%28INCY%29+PT+Raised+to+%24110+at+JPMorgan/26804668.html Thu, 23 Jul 2026 07:39:55 -0400 INCY http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Incyte+%28INCY%29/26791890.html <p>H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating and $140.00 price target on Incyte (NASDAQ: INCY).</p><p>The analyst commented: "Incyte entered a global license agreement with Halozyme (HALO; Kapoor; Buy) to develop ENHANZE-enabled subQ formulations of INCA033989 ('989). Halozyme will receive an undisclosed upfront payment, development, regulatory and commercial milestones, and royalties, while Incyte can nominate up to two additional targets. While the royalty rate was not disclosed, Halozyme’s economics in comparable deals have typically included a mid-single-digit percentage royalty. Prior to this announcement, we had been messaging to investors that creating a hyaluronidase-enabled subQ alternative to the planned enFuse http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Incyte+%28INCY%29/26791890.html Tue, 21 Jul 2026 06:51:58 -0400 INCY http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+Tray+Thomas/26789812.html si-local-file:///var/storage/secattach/20260720/26789812.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+Tray+Thomas/26789812.html Mon, 20 Jul 2026 16:11:00 -0400 INCY O.00160346 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+Tray+Thomas/26789812.html si-local-file:///var/storage/secattach/20260720/26789812.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+Tray+Thomas/26789812.html Mon, 20 Jul 2026 16:11:00 -0400 INCY O.00160346 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+Mayes+Patrick+A/26789802.html si-local-file:///var/storage/secattach/20260720/26789802.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+Mayes+Patrick+A/26789802.html Mon, 20 Jul 2026 16:10:00 -0400 INCY O.00160346 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+Mayes+Patrick+A/26789802.html si-local-file:///var/storage/secattach/20260720/26789802.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+Mayes+Patrick+A/26789802.html Mon, 20 Jul 2026 16:10:00 -0400 INCY O.00160346 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+Stein+Steven+H/26789808.html si-local-file:///var/storage/secattach/20260720/26789808.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+Stein+Steven+H/26789808.html Mon, 20 Jul 2026 16:10:00 -0400 INCY O.00160346 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+Stein+Steven+H/26789808.html si-local-file:///var/storage/secattach/20260720/26789808.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+Stein+Steven+H/26789808.html Mon, 20 Jul 2026 16:10:00 -0400 INCY O.00160346 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+Gardner+David+H/26789775.html si-local-file:///var/storage/secattach/20260720/26789775.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+Gardner+David+H/26789775.html Mon, 20 Jul 2026 16:09:00 -0400 INCY O.00160346 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+Gardner+David+H/26789775.html si-local-file:///var/storage/secattach/20260720/26789775.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+Gardner+David+H/26789775.html Mon, 20 Jul 2026 16:09:00 -0400 INCY O.00160346 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+Basi+Ramitpal+K/26789779.html si-local-file:///var/storage/secattach/20260720/26789779.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+Basi+Ramitpal+K/26789779.html Mon, 20 Jul 2026 16:09:00 -0400 INCY O.00160346 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+Basi+Ramitpal+K/26789779.html si-local-file:///var/storage/secattach/20260720/26789779.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+Basi+Ramitpal+K/26789779.html Mon, 20 Jul 2026 16:09:00 -0400 INCY O.00160346 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+Issa+Mohamed+Khairie/26789784.html si-local-file:///var/storage/secattach/20260720/26789784.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+Issa+Mohamed+Khairie/26789784.html Mon, 20 Jul 2026 16:09:00 -0400 INCY O.00160346 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+Issa+Mohamed+Khairie/26789784.html si-local-file:///var/storage/secattach/20260720/26789784.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+Issa+Mohamed+Khairie/26789784.html Mon, 20 Jul 2026 16:09:00 -0400 INCY O.00160346 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+CAGNONI+PABLO+J/26789786.html si-local-file:///var/storage/secattach/20260720/26789786.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+CAGNONI+PABLO+J/26789786.html Mon, 20 Jul 2026 16:09:00 -0400 INCY O.00160346 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+CAGNONI+PABLO+J/26789786.html si-local-file:///var/storage/secattach/20260720/26789786.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+CAGNONI+PABLO+J/26789786.html Mon, 20 Jul 2026 16:09:00 -0400 INCY O.00160346 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+Meury+William/26789761.html si-local-file:///var/storage/secattach/20260720/26789761.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+Meury+William/26789761.html Mon, 20 Jul 2026 16:08:00 -0400 INCY O.00160346 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+Meury+William/26789761.html si-local-file:///var/storage/secattach/20260720/26789761.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+Meury+William/26789761.html Mon, 20 Jul 2026 16:08:00 -0400 INCY O.00160346 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+Hoffman+Richard+A./26789766.html si-local-file:///var/storage/secattach/20260720/26789766.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+Hoffman+Richard+A./26789766.html Mon, 20 Jul 2026 16:08:00 -0400 INCY O.00160346 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+Hoffman+Richard+A./26789766.html si-local-file:///var/storage/secattach/20260720/26789766.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INCYTE+CORP+++++++++++++++For%3A+Jul+16++Filed+by%3A+Hoffman+Richard+A./26789766.html Mon, 20 Jul 2026 16:08:00 -0400 INCY O.00160346 http://www.streetinsider.com/Corporate+News/Halozyme+and+Incyte+sign+drug+delivery+licensing+agreement/26787292.html <p>Halozyme Therapeutics (NASDAQ: HALO) has entered into a global collaboration and license agreement with Incyte (NASDAQ: INCY) to develop subcutaneous formulations of INCA033989, a mutant calreticulin (mutCALR)-targeted monoclonal antibody being studied in patients with mutCALR-expressing myeloproliferative neoplasms.</p> <p>The agreement grants Incyte rights to use Halozyme's ENHANZE drug delivery technology with its mutCALR development program. Incyte also holds an option to nominate up to two additional targets for use with the technology.</p> <p>Under the terms of the deal, Halozyme will receive an upfront payment from Incyte, along with potential milestone payments and royalties on net sales of any commercialized medicines that use the http://www.streetinsider.com/Corporate+News/Halozyme+and+Incyte+sign+drug+delivery+licensing+agreement/26787292.html Mon, 20 Jul 2026 08:00:40 -0400 A.30035300 HALO INCY O.00160346 O.00978404 O.20947283 http://www.streetinsider.com/Corporate+News/Halozyme+and+Incyte+sign+drug+delivery+licensing+agreement/26787292.html <p>Halozyme Therapeutics (NASDAQ: HALO) has entered into a global collaboration and license agreement with Incyte (NASDAQ: INCY) to develop subcutaneous formulations of INCA033989, a mutant calreticulin (mutCALR)-targeted monoclonal antibody being studied in patients with mutCALR-expressing myeloproliferative neoplasms.</p> <p>The agreement grants Incyte rights to use Halozyme's ENHANZE drug delivery technology with its mutCALR development program. Incyte also holds an option to nominate up to two additional targets for use with the technology.</p> <p>Under the terms of the deal, Halozyme will receive an upfront payment from Incyte, along with potential milestone payments and royalties on net sales of any commercialized medicines that use the http://www.streetinsider.com/Corporate+News/Halozyme+and+Incyte+sign+drug+delivery+licensing+agreement/26787292.html Mon, 20 Jul 2026 08:00:40 -0400 A.30035300 HALO INCY O.00160346 O.00978404 O.20947283 http://www.streetinsider.com/Corporate+News/Halozyme+and+Incyte+sign+drug+delivery+licensing+agreement/26787292.html <p>Halozyme Therapeutics (NASDAQ: HALO) has entered into a global collaboration and license agreement with Incyte (NASDAQ: INCY) to develop subcutaneous formulations of INCA033989, a mutant calreticulin (mutCALR)-targeted monoclonal antibody being studied in patients with mutCALR-expressing myeloproliferative neoplasms.</p> <p>The agreement grants Incyte rights to use Halozyme's ENHANZE drug delivery technology with its mutCALR development program. Incyte also holds an option to nominate up to two additional targets for use with the technology.</p> <p>Under the terms of the deal, Halozyme will receive an upfront payment from Incyte, along with potential milestone payments and royalties on net sales of any commercialized medicines that use the http://www.streetinsider.com/Corporate+News/Halozyme+and+Incyte+sign+drug+delivery+licensing+agreement/26787292.html Mon, 20 Jul 2026 08:00:40 -0400 A.30035300 HALO INCY O.00160346 O.00978404 O.20947283 http://www.streetinsider.com/Corporate+News/Halozyme+and+Incyte+sign+drug+delivery+licensing+agreement/26787292.html <p>Halozyme Therapeutics (NASDAQ: HALO) has entered into a global collaboration and license agreement with Incyte (NASDAQ: INCY) to develop subcutaneous formulations of INCA033989, a mutant calreticulin (mutCALR)-targeted monoclonal antibody being studied in patients with mutCALR-expressing myeloproliferative neoplasms.</p> <p>The agreement grants Incyte rights to use Halozyme's ENHANZE drug delivery technology with its mutCALR development program. Incyte also holds an option to nominate up to two additional targets for use with the technology.</p> <p>Under the terms of the deal, Halozyme will receive an upfront payment from Incyte, along with potential milestone payments and royalties on net sales of any commercialized medicines that use the http://www.streetinsider.com/Corporate+News/Halozyme+and+Incyte+sign+drug+delivery+licensing+agreement/26787292.html Mon, 20 Jul 2026 08:00:40 -0400 A.30035300 HALO INCY O.00160346 O.00978404 O.20947283